Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
AIM: The increase of prostate-specific antigen (PSA) after radical retropubic prostatectomy (RP) or external beam radiotherapy (EBRT) is the most sensitive tool for detecting prostate cancer (PCa) recurrence, although this measure cannot distinguish between local, regional, or distant recurrence. The aim of this meta-analysis was to evaluate the diagnostic performance of 18F-choline and 11C-choline PET or PET/CT in detection of locoregional or distant metastases in PCa. MATERIALS AND METHODS: Medline, Web of Knowledge, and Google Scholar search was carried out in order to select English-language articles dealing with diagnostic performance of both 18F-choline and 11C-choline PET for the detection of PCa recurrence after RP or EBRT. Articles were included only if absolute numbers of true-positive, true-negative, false-positive, and false-negative test results were available or derivable from the text and regarded local, lymph node, and distant metastases. Reviews, clinical reports, and editorial articles were excluded. All complete studies were re-analyzed thus performing a quantitative analysis. RESULTS: From the years 2000 to 2012, we found 53 complete articles that critically evaluated the role of choline PET in restaging patients with PCa recurrence. The meta-analysis was carried out and dealt with 19 selected studies (12 studies for all sites of disease, 3 for lymph node metastases, and 4 for local recurrence), with a total of 1555 patients. The meta-analysis provided a pooled sensitivity of 85.6% (95% CI: 82.9%-88.1%) and pooled specificity of 92.6% (95% CI: 90.1%-94.6%) for all sites of disease (prostatic fossa, lymph nodes, and bone), a pooled sensitivity of 75.4% (95% CI: 66.9%-82.6%) and pooled specificity of 82% (95% CI: 68.6%-91.4%) for prostatic fossa recurrence, and a pooled sensitivity of 100% (95% CI: 90.5%-100%) and pooled specificity of 81.8% (95% CI: 48.2%-97.7%) for lymph node metastases. The heterogeneity ranged between 0.00% and 88.6%. The diagnostic odds ratios were 62.123 (95% CI: 24.783-155.72), 5.869 (95% CI: 1.818-18.946), and 138.57 (95% CI: 11.27-1703.8), respectively, for all sites of disease, local recurrence, and lymph node disease. CONCLUSIONS: Choline PET and PET/CT represent high sensitivity and specificity techniques for the detection of locoregional and distant metastases in PCa patients with recurrence of disease. Moreover, a high diagnostic odds ratio was found for the identification of lymph node disease in patients with biochemical recurrence of PCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592
Meta-DiSc: a software for meta-analysis of test accuracy data
Zamora, J., Abraira, V., Muriel, A., Khan, K., & Coomarasamy, A. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-31 · Cited by 1,883
Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer: A Randomized Clinical Trial
Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2329 · Cited by 897
EAU Guidelines on Prostate Cancer
Aus, G., Abbou, C. C., Bolla, M., Heidenreich, A., Schmid, H.-P., van Poppel, H., Wolff, J., & Zattoni, F. (2005) · European Urology · doi:10.1016/j.eururo.2005.06.001 · Cited by 579
Self-citationDoes blinding of readers affect the results of meta-analyses?
Berlin, J. A. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62352-5 · Cited by 478 · cited 1×
“Observers were not blinded with regard to unnecessary information as the journal name, the authors, the authors’ affiliation, or year of publication because such blinding has been shown to be unnecessary.(23) The reviewers (FaZ and AG) examined relevant studies with Quality Assessment Tool for Diagnostic Accuracy Stud…”
BackgroundKrause, B. J., Souvatzoglou, M., Tuncel, M., Herrmann, K., Buck, A. K., Praus, C., Schuster, T., Geinitz, H., Treiber, U., & Schwaiger, M. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0581-4 · Cited by 367
Cimitan, M., Bortolus, R., Morassut, S., Canzonieri, V., Garbeglio, A., Baresic, T., Borsatti, E., Drigo, A., & Trovò, M. G. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0150-2 · Cited by 312
Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer
Husarik, D. B., Miralbell, R., Dubs, M., John, H., Giger, O. T., Gelet, A., Cservenyàk, T., & Hany, T. F. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0552-9 · Cited by 295
Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline
Jadvar, H. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077941 · Cited by 290
Giovacchini, G., Picchio, M., Coradeschi, E., Bettinardi, V., Gianolli, L., Scattoni, V., Cozzarini, C., Di Muzio, N., Rigatti, P., Fazio, F., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1253-3 · Cited by 270
Roberts, S. G., Blute, M. L., Bergstralh, E. J., Slezak, J. M., & Zincke, H. (2001) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62406-3 · Cited by 252
Scattoni, V., Picchio, M., Suardi, N., Messa, C., Freschi, M., Roscigno, M., Da Pozzo, L., Bocciardi, A., Rigatti, P., & Fazio, F. (2007) · European Urology · doi:10.1016/j.eururo.2007.03.032 · Cited by 250
Heinisch, M., Dirisamer, A., Loidl, W., Stoiber, F., Gruy, B., Haim, S., & Langsteger, W. (2006) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0023-2 · Cited by 191
Picchio, M., Briganti, A., Fanti, S., Heidenreich, A., Krause, B. J., Messa, C., Montorsi, F., Reske, S. N., & Thalmann, G. N. (2011) · European Urology · doi:10.1016/j.eururo.2010.09.004 · Cited by 190
Seltzer, M., Barbaric, Z. L., Belldegrun, A. S., Naitoh, J., Dorey, F. J., Phelps, M. E., Gambhir, S. S., & Hoh, C. K. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68277-8 · Cited by 186
Picchio, M., Spinapolice, E. G., Fallanca, F., Crivellaro, C., Giovacchini, G., Gianolli, L., & Messa, C. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1920-z · Cited by 153
Management of prostate-specific antigen relapse in prostate cancer: A European consensus
BOCCON-GIBOD, L., Djavan, B., Hammerer, P. G., Hoeltl, W., Kattan, M. W., Prayer‐Galetti, T., Teillac, P., & Tunn, U. W. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.00184.x · Cited by 131
Giovacchini, G., Picchio, M., Scattoni, V., Parra, R. G., Briganti, A., Gianolli, L., Montorsi, F., & Messa, C. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1403-7 · Cited by 127
Schilling, D., Schlemmer, H. P., Wagner, P. H., Böttcher, P., Merseburger, A. S., Aschoff, P., Bares, R., Pfannenberg, C., Ganswindt, U., Corvin, S., et al. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07592.x · Cited by 121
Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer
Morgan, W. R., Bergstralh, E. J., & Zincke, H. (1993) · Urology · doi:10.1016/0090-4295(93)90159-8 · Cited by 110
Schillaci, O., Calabria, F. F., Tavolozza, M., Caracciolo, C. R., Agrò, E. F., Miano, R., Orlacchio, A., Danieli, R., & Simonetti, G. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2030-7 · Cited by 98
Souvatzoglou, M., Krause, B. J., Pürschel, A., Thamm, R., Schuster, T., Buck, A. K., Zimmermann, F. B., Molls, M., Schwaiger, M., & Geinitz, H. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.005 · Cited by 97
Management of recurrent disease after radical prostatectomy
Bott, S. (2004) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500732 · Cited by 90
Breeuwsma, A. J., Pruim, J., van den Bergh, A. C. M., Leliveld, A. M., Nijman, R. J. M., Dierckx, R., & de Jong, I. J. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.090 · Cited by 90
Role of 18F-Choline PET/CT in Biochemically Relapsed Prostate Cancer After Radical Prostatectomy
Marzola, M. C., Chondrogiannis, S., Ferretti, A., Grassetto, G., Rampin, L., Massaro, A., Castellucci, P., Picchio, M., AL-NAHHAS, A. M., Colletti, P. M., et al. (2012) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e318266cc38 · Cited by 77
Self-citationThree-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence
Steiner, C., Vees, H., Zaidi, H., Wissmeyer, M., Berrebi, O., Kossovsky, M. P., Khan, H. G., Miralbell, R., Ratib, O. M., & Buchegger, F. (2009) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0194 · Cited by 59
Winter, A., Uphoff, J., Henke, R., & Wawroschek, F. (2010) · Urologia Internationalis · doi:10.1159/000296298 · Cited by 57
Cited by
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv257 · Cited by 322
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Rowe, S. P., Macura, K. J., Mena, E., Blackford, A. L., Nadal, R., Antonarakis, E. S., Eisenberger, M., Carducci, M., Fan, H., Dannals, R. F., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0957-6 · Cited by 258
A urologist’s perspective on prostate cancer imaging: past, present, and future
George, A. K., Turkbey, B., Valayil, S. G., Muthigi, A., Mertan, F., Kongnyuy, M., & Pinto, P. A. (2016) · Abdominal Radiology · doi:10.1007/s00261-016-0751-6 · Cited by 30
“The major advantage conferred in Choline PET appears to be a pooled sensitivity of 86% and specificity of 93% [79].”
Background
Metadata
- Authors
- Evangelista, L., Zattoni, F., Guttilla, A., Saladini, G., Zattoni, F., Colletti, P. M., & Rubello, D.
- Venue
- Clinical Nuclear Medicine
- Published
- 2013-05
- Volume
- 38
- Issue
- 5
- Pages
- 305-314
- ISSN
- 0363-9762 (ISSN-L)
- OpenAlex
- W1995205917
- Cited by
- 278
- References
- 28
- FWCI
- 24.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.